101 related articles for article (PubMed ID: 31374291)
1. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth.
Li X; He S; Tian Y; Weiss RM; Martin DT
Cell Signal; 2019 Nov; 63():109381. PubMed ID: 31374291
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu S; Grande F; Garofalo A; Neamati N
Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target.
Martin DT; Shen H; Steinbach-Rankins JM; Zhu X; Johnson KK; Syed J; Saltzman WM; Weiss RM
Mol Cancer Ther; 2019 Feb; 18(2):413-420. PubMed ID: 30381445
[TBL] [Abstract][Full Text] [Related]
4. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
5. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis.
He S; Li G; Schätzlein AG; Humphrey PA; Weiss RM; Uchegbu IF; Martin DT
Cell Signal; 2021 May; 81():109931. PubMed ID: 33529758
[TBL] [Abstract][Full Text] [Related]
7. Sodium Selenite Enhanced the Anti-proliferative Effect of MEK-ERK Inhibitor in Thyroid Cancer Cells.
Kim JB; Yang EY; Woo J; Kwon H; Lim W; Moon BI
In Vivo; 2020; 34(1):185-190. PubMed ID: 31882478
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
9. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
[TBL] [Abstract][Full Text] [Related]
11. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells.
Chen RJ; Ho YS; Guo HR; Wang YJ
Toxicol Sci; 2010 May; 115(1):118-30. PubMed ID: 20106947
[TBL] [Abstract][Full Text] [Related]
12. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
13. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
[TBL] [Abstract][Full Text] [Related]
14. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144.
Pozios I; Hering NA; Guenzler E; Arndt M; Elezkurtaj S; Knösel T; Bruns CJ; Margonis GA; Beyer K; Seeliger H
J Cancer Res Clin Oncol; 2023 Jan; 149(1):271-280. PubMed ID: 36495330
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia.
Wang ZQ; Wu DC; Huang FP; Yang GY
Brain Res; 2004 Jan; 996(1):55-66. PubMed ID: 14670631
[TBL] [Abstract][Full Text] [Related]
16. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2.
Park BH; Lim JE; Jeon HG; Seo SI; Lee HM; Choi HY; Jeon SS; Jeong BC
Oncotarget; 2016 Sep; 7(39):63870-63886. PubMed ID: 27564099
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mitogen-activated protein kinase signaling pathway sensitizes breast cancer cells to endoplasmic reticulum stress-induced apoptosis.
Yang F; Tang XY; Liu H; Jiang ZW
Oncol Rep; 2016 Apr; 35(4):2113-20. PubMed ID: 26796921
[TBL] [Abstract][Full Text] [Related]
20. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
Yip-Schneider MT; Schmidt CM
Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
